• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    11/1/24 4:35:56 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SUPN alert in real time by email
    SC 13G/A 1 d885694dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Supernus Pharmaceuticals Inc

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    868459108

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.868459108

     

     1.   

     Names of Reporting Persons

     

     Macquarie Group Limited

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Sydney, New South Wales Australia

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,631,897 deemed beneficially owned due to reporting person’s ownership of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust whose individual holdings are shown on the following forms.

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.78%

    12.  

     Type of Reporting Person (See Instructions)

     

     HC

     

    Page 2 of 13


    CUSIP No.868459108

     

     1.   

     Names of Reporting Persons

     

     Macquarie Management Holdings Inc

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     State of Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     2,631,897

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     2,631,897

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,631,897 deemed beneficially owned due to reporting person’s ownership of Macquarie Investment Management Business Trust

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☒

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.78%

    12.  

     Type of Reporting Person (See Instructions)

     

     HC

     

    Page 3 of 13


    CUSIP No.868459108

     

     1.   

     Names of Reporting Persons

     

     Macquarie Investment Management Business Trust

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     State of Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     2,631,897

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     2,631,897

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,631,897

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☒

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     4.78%

    12.  

     Type of Reporting Person (See Instructions)

     

     IA

     

    Page 4 of 13


    Item 1.
       (a)  

    Name of Issuer

    Supernus Pharmaceuticals Inc

       (b)  

    Address of Issuer’s Principal Executive Offices

    9715 Key West Avenue, Rockville, MD 20850

    Item 2.
       (a)  

    Name of Person Filing

    This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc and Macquarie Investment Management Business Trust

       (b)  

    Address of Principal Business Office or, if none, Residence

    The principal business address of Macquarie Group Limited is Level 1, 1 Elizabeth Street, Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 610 Market Street, Philadelphia, PA 19106.

       (c)  

    Citizenship

    Macquarie Group Limited - Sydney, New South Wales, Australia Corporation

    Macquarie Management Holdings Inc., Macquarie Investment Management Business Trust– incorporated or formed under the laws of the State of Delaware.

       (d)  

    Title of Class of Securities

    Common Stock

       (e)  

    CUSIP Number

    868459108

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)   ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)   ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)   ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)   ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)   ☒    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)   ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)   ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)   ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)   ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
       (k)   ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Page 5 of 13


    Item 4.    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a)   

    Amount beneficially owned:

    See responses on the cover page hereto.

       (b)   

    Percent of class:

    See responses on the cover page hereto.

       (c)   

    Number of shares as to which the person has:

     

          (i)   

    Sole power to vote or to direct the vote

    See responses on the cover page hereto.

          (ii)   

    Shared power to vote or to direct the vote

    0

          (iii)   

    Sole power to dispose or to direct the disposition of

    See responses on the cover page hereto.

          (iv)   

    Shared power to dispose or to direct the disposition of

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following 

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    See Exhibit A.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Page 6 of 13


    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Group Limited    November 1, 2024
       Date
    /s/ Philip Alexander    /s/ Charles Glorioso
    Signature    Signature
          

    Philip Alexander

    Associate Director

      

    Charles Glorioso

    Division Director

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Management Holdings, Inc.    November 1, 2024
       Date
    /s/ Marty Wolin   
    Signature   
        

    Marty Wolin

    Chief Compliance Officer

      

     

    Macquarie Investment Management Business Trust    November 1, 2024
       Date
    /s/ Marty Wolin   
    Signature   
        

    Marty Wolin

    Chief Compliance Officer

      

     

     

    Page 7 of 13

    Get the next $SUPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SUPN

    DatePrice TargetRatingAnalyst
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    1/3/2023$44.00 → $45.00Buy
    Jefferies
    12/1/2021$40.00 → $44.00Buy
    Jefferies
    More analyst ratings

    $SUPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

      2/19/25 7:05:55 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Supernus Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Supernus Pharma with a rating of Overweight and set a new price target of $57.00

      1/6/25 8:47:11 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $41.00 previously

      9/11/24 7:45:40 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Financials

    Live finance-specific insights

    See more
    • Supernus Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10.3) million, compared to operating loss of $(3.2) million in 2024. First quarter adjusted operating earnings (non-GAAP)(1) increased 16% to $25.9 million.ONAPGO™ (apomorphine hydrochloride

      5/6/25 4:08:06 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

      ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2025 financial and business results on Tuesday, May 6, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the call will

      4/23/25 5:14:00 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full year 2023.Fourth quarter 2024 net sales of GOCOVRI® increased 15% to $36.9 million, compared to the same period in 2023. Full year net sales of GOCOVRI increased 9% to $130.8 million, compared to full year 2023.Full year 2024 revenues increased 9% to $661.8 million, compared to the same period in 2023; Full year 2024 total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1) increased 25%, compared to full year of 2023.Full year 2024 operating earnings of $81.7 million, co

      2/25/25 4:01:52 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Supernus Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10.3) million, compared to operating loss of $(3.2) million in 2024. First quarter adjusted operating earnings (non-GAAP)(1) increased 16% to $25.9 million.ONAPGO™ (apomorphine hydrochloride

      5/6/25 4:08:06 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

      ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2025 financial and business results on Tuesday, May 6, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the call will

      4/23/25 5:14:00 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus to Participate in Two Upcoming Investor Conferences

      ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Barclays Global Healthcare ConferenceDate: Tuesday, March 11, 2025Fireside chat:  12:30 p.m. ETPlace: Loews Miami Beach Hotel, Miami, Fla.   Jefferies Biotech on the Beach SummitDate: Wednesday, March 12, 2025Place: Ritz-Carlton South Beach, Miami, Fla.    Investors interested in arranging a meeting with the Company'

      3/4/25 4:30:40 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Leadership Updates

    Live Leadership Updates

    See more
    • Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

      Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

      10/16/23 5:34:21 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Supernus Pharmaceuticals Inc.

      10-Q - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      5/6/25 4:20:44 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      5/6/25 4:14:18 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Supernus Pharmaceuticals Inc.

      DEFA14A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      4/30/25 4:19:32 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO Khattar Jack A. acquired 16,850 shares and disposed of 16,850 shares, increasing direct ownership by 2% to 1,008,683 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      4/3/25 4:27:28 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Khattar Jack A. converted options into 35,000 shares and covered exercise/tax liability with 16,805 shares, increasing direct ownership by 2% to 991,833 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      3/11/25 4:17:35 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Senior Vice-President & CFO Dec Timothy C converted options into 3,800 shares and covered exercise/tax liability with 2,017 shares, increasing direct ownership by 16% to 12,681 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      3/11/25 4:15:41 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

      SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      11/14/24 5:14:42 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

      SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      11/1/24 4:35:56 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Supernus Pharmaceuticals Inc.

      SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      10/31/24 11:55:00 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care